Corporate Video

Enanta Pharmaceuticals is using its robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets:  Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV).

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.  Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its newest treatment for chronic HCV infection. This HCV regimen is sold under the trade names MAVYRET™ (U.S) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir).

Enanta’s wholly-owned pipeline includes EDP-938, an N-protein inhibitor for RSV with positive top-line data from a Phase 2 challenge study, EDP-305, an FXR agonist product candidate for NASH and PBC in two Phase 2 studies and EDP-514, our core inhibitor candidate for HBV is currently in a phase 1 clinical study. 

View our pipeline.

Enanta is headquartered in Watertown, Massachusetts.